Officials from the Anhui Provincial Medical Products Administration Visit Our Company for an Inspection and Research Tour

On April 22, 2026, Zhang Lei, Member of the Party Leadership Group and Deputy Director of the Anhui Provincial Medical Products Administration, together with Wang Changxiang, Director of the Drug Manufacturing Supervision Division, and other officials, visited Kangrong Pharmaceutical to learn about the company’s development and quality management practices. During the visit, the delegation held an in-depth discussion with company representatives regarding business operations and the company’s practical needs.

At the meeting, General Manager Yang Chunjie provided the delegation with a detailed overview of the company’s current development and future plans, production arrangements for existing products, and registration applications for products under development. Particular emphasis was placed on the contract manufacturing and quality assurance of Moxifloxacin Hydrochloride and Sodium Chloride Injection, a product included in China’s centralized procurement program.

Deputy Director Zhang recognized the company’s positive development momentum and strong commitment to quality management, encouraging Kangrong Pharmaceutical to continue expanding and strengthening its business. He also provided comprehensive responses to the practical challenges raised by the company and expressed close attention to its development needs.

Deputy Director Zhang further emphasized that pharmaceutical safety is directly related to public health and well-being. He urged the company to maintain its current positive momentum, strictly comply with the requirements and guidelines issued by the National Medical Products Administration (NMPA) and the Anhui Provincial Medical Products Administration, and place particular emphasis on post-marketing risk management to ensure the safety and health of patients.

On behalf of the company, General Manager Yang Chunjie expressed his appreciation to the Anhui Provincial Medical Products Administration for fostering a supportive business environment and establishing effective communication and service mechanisms. He reaffirmed Kangrong Pharmaceutical’s commitment to continuously strengthening its core competitiveness and contributing to the sustainable development and advancement of the pharmaceutical industry.